Albany Molecular Research (AMRI) Narrows Q3 Loss; Lowers FY11 Contract Revs Outlook
Tweet
Share
E-mailGet Alerts AMRI Hot Sheet
Join SI Premium – FREE
Albany Molecular Research (NASDAQ: AMRI) reported Q3 EPS of ($0.19), versus ($0.33) reported last year. Revenue for the quarter came in at $50.23 million, versus $50.62 million reported last year.
Sees Q4 2011 contract revenue of $41-$45 million.
Sees FY2011 contract revenue of $171-$175 million.
Sees Q4 2011 contract revenue of $41-$45 million.
Sees FY2011 contract revenue of $171-$175 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- Southland Holdings (SLND) Misses Q2 EPS by 122c
- Logistic Properties of the Americas (LPA) Reports Q2 results
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
